Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

PURPOSE: Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Res Treat
Main Authors: Kim, Seok-Jin, Hyeon, Jiyeon, Cho, Inju, Ko, Young Hyeh, Kim, Won Seog
Format: Artigo
Sprog:Inglês
Udgivet: Korean Cancer Association 2019
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6473267/
https://ncbi.nlm.nih.gov/pubmed/30025443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.191
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker